“Repeat-dose toxicity studies were performed in cynomolgus monkeys, because comparable potency was shown for brodalumab for the inhibition of monkey IL-17RA compared to human IL-17RA”
Comparable potency against monkey and human IL-17RA; no cross-reactivity with rodent IL-17RA; dog binding inconclusive; rabbit unsuitable (ADA)
“because comparable potency was shown for brodalumab for the inhibition of monkey IL-17RA compared to human IL-17RA, whereas brodalumab does not cross-react with rodent IL-17RA and assessment of binding to dog IL-17RA was inconclusive.”